Ferring International Center SA:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Ferring International Center SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C3328)・商品コード:DATA904C3328
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:64
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Ferring International Center SA (Ferring) researches, develops and markets pharmaceutical products. The company offers pharmaceutical products in the fields of reproductive health, gastroenterology, endocrinology, urology and orthopedics. Some of the marketed products include Rekovelle (follitropin delta), for controlled ovarian stimulation; Menopur (HP-hMG) for female and male infertility; Firmagon (degarelix) for prostate cancer; and Pentasa (mesalazine) for inflammatory bowel diseases. Its pipeline products encompass FE 999310 for infertility; FE 202767 for Lactation; Testavan for male hypogonadism; and Prefix for lumbar spine fusion, among others. Ferring conducts R&D on biotechnology derived medicines such as recombinant proteins and other biologics. It has production facilities in Europe, Asia and a manufacturing site in the US. Ferring is headquartered in Saint-Prex, Switzerland.

Ferring International Center SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ferring International Center SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ferring International Center SA, Medical Devices Deals, 2012 to YTD 2018 10
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ferring International Center SA, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Ferring International Center Acquire Ex-US Vitaros Assets and Rights from Apricus Biosciences 13
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women’s Health 15
Ferring Pharma to Acquire Novel Drug Delivery Technology from CTCBIO 16
Ferring Pharma Acquires Assets from BioSurface Engineering 17
Ferring Pharma Acquires Ddavp from Sanofi 18
Ferring International To Acquire Assets Of Al-Kindi Pharma For US$6 Million 19
Partnerships 20
Enteris BioPharma Enters into Agreement with Ferring Pharma 20
Ferring Pharma and Chinese Academy of Sciences Enter into Agreement 21
LIDDS Enters into Research Agreement with Ferring Pharma 22
Ferring International and Alrise Biosystems Enter into Co-Development Agreement 23
Ferring Pharma Enters into Agreement with CD Investments 24
Ferring Pharma Enters into Partnership with ICF 25
Ferring Pharma Enters into Agreement with Intralytix 26
Ferring International Center Enters into Agreement with Ache Laboratorios Farmaceuticos 27
Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 28
Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 29
Ferring Pharma Enters into Co-Development Agreement with Roche 30
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 31
Licensing Agreements 32
Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 32
Ferring International Enters into Licensing Agreement with Enteris BioPharma 33
Ferring International Enters into Licensing Agreement with IMAB 34
Levo Therapeutics Enters into Licensing Agreement with Ferring Pharma 35
Ferring Pharma Enters into Licensing Agreement with Seikagaku 36
Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 37
TxCell Enters into Licensing Agreement with Ferring International for Ovasave 38
Acquisition 40
Ferring Pharma Acquires Rebiotix 40
Ferring International Center SA – Key Competitors 41
Ferring International Center SA – Key Employees 42
Ferring International Center SA – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 47
Corporate Communications 47
Oct 02, 2017: Ferring appoints Klaus Dugi as Executive Vice President and Chief Medical Officer 47
May 23, 2017: Ferring commits $10 million to March of Dimes to expand research needed to end preterm birth 48
Apr 03, 2017: Ferring appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer 49
Product News 50
08/23/2017: Rebiotix to Present on RBX2660 at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference 50
08/23/2017: Rebiotix to Present on RBX7455 at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference 51
02/12/2018: Rebiotix Develops Microbiome Health Index to Identify Indicators for Microbiome Restoration 52
02/06/2017: Rebiotix to Present on RBX7455 at BIO CEO & Investor Conference 53
Product Approvals 54
Mar 15, 2018: Ferring announces positive outcome of European Decentralised Procedure for Testavan, a treatment for men with hypogonadism 54
Clinical Trials 55
Nov 29, 2017: Rebiotix Announces Expansion of Phase 1 Trial of the Companys Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms 55
Nov 15, 2017: Rebiotix to Present on its Anti-Bacterial Agent RBX2660 at 29th Annual Piper Jaffray Healthcare Conference 56
Nov 15, 2017: Rebiotix to Present on its Anti-Bacterial Agent RBX7455 at 29th Annual Piper Jaffray Healthcare Conference 57
Oct 16, 2017: New Clinical Data and Microbiome Research from Rebiotix’s Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017 58
Oct 12, 2017: Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017 59
Oct 04, 2017: Presentations at ID Week 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotixs RBX2660 Phase 2 Studies 60
Aug 07, 2017: Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection 62
Jan 04, 2017: Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Ferring International Center SA, Pharmaceuticals & Healthcare, Key Facts 2
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ferring International Center SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ferring International Center SA, Deals By Therapy Area, 2012 to YTD 2018 9
Ferring International Center SA, Medical Devices Deals, 2012 to YTD 2018 10
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ferring International Center Acquire Ex-US Vitaros Assets and Rights from Apricus Biosciences 13
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health 15
Ferring Pharma to Acquire Novel Drug Delivery Technology from CTCBIO 16
Ferring Pharma Acquires Assets from BioSurface Engineering 17
Ferring Pharma Acquires Ddavp from Sanofi 18
Ferring International To Acquire Assets Of Al-Kindi Pharma For US$6 Million 19
Enteris BioPharma Enters into Agreement with Ferring Pharma 20
Ferring Pharma and Chinese Academy of Sciences Enter into Agreement 21
LIDDS Enters into Research Agreement with Ferring Pharma 22
Ferring International and Alrise Biosystems Enter into Co-Development Agreement 23
Ferring Pharma Enters into Agreement with CD Investments 24
Ferring Pharma Enters into Partnership with ICF 25
Ferring Pharma Enters into Agreement with Intralytix 26
Ferring International Center Enters into Agreement with Ache Laboratorios Farmaceuticos 27
Ferring Pharma Enters into Co-Development Agreement with Karolinska Institutet 28
Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 29
Ferring Pharma Enters into Co-Development Agreement with Roche 30
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 31
Ferring Pharma Enters into Licensing Agreement with Ligand Pharma 32
Ferring International Enters into Licensing Agreement with Enteris BioPharma 33
Ferring International Enters into Licensing Agreement with IMAB 34
Levo Therapeutics Enters into Licensing Agreement with Ferring Pharma 35
Ferring Pharma Enters into Licensing Agreement with Seikagaku 36
Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 37
TxCell Enters into Licensing Agreement with Ferring International for Ovasave 38
Ferring Pharma Acquires Rebiotix 40
Ferring International Center SA, Key Competitors 41
Ferring International Center SA, Key Employees 42
Ferring International Center SA, Other Locations 43
Ferring International Center SA, Subsidiaries 43

List of Figures
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ferring International Center SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ferring International Center SA, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Ferring International Center SA:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C3328)販売に関する免責事項を必ずご確認ください。
★調査レポート[Ferring International Center SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆